Results
Pappas Capital LLC
08/20/2007 | Press release | Archived content
Methylgene and Pharmion announce collaboration to develop sirtuin...
News | 08. 20. 2007
MethylGene Inc. (TSX:MYG) and Pharmion Corporation (NASDAQ:PHRM) today announced a research collaboration for the development of novel small molecule inhibitors targeting sirtuins, a separate and distinct class of histone deacetylase enzymes (Class 3 HDACs) implicated in cell survival and death.
Pappas Capital LLC published this content on August 20, 2007, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:12 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]